MENU

Can Gilead Sciences (GILD) Stock Reach $190?

a developer of therapeutic products and treatments for life threatening diseases

Industry: #Biotechnology
A.I.Advisor
published price charts
A.I.Advisor
Nov 08, 2026

Can Gilead Sciences (GILD) Stock Reach $190?

Key Takeaways

  • The central target of $190 is the average of the verified analyst price targets that sit above the current share price, not a published consensus figure.
  • At a recent close near $166.89, reaching $190 would require roughly a 14% advance — a substantial but not extreme move.
  • Across 14 individual targets reviewed, the full range runs from $131 to $200, and the overall mean of all targets is about $177.
  • Bullish targets rest on the strength of Gilead's HIV franchise — including Biktarvy and the newer Yeztugo PrEP launch — plus oncology optionality.
  • Cautious targets reflect oncology pipeline setbacks, margin pressure, and early generic competition for Yeztugo.
  • You can explore Major News, Today's Price Move, Forecast, and Earnings for GILD on additional pages.
  • For automated stock monitoring, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Gilead Sciences, Inc. (GILD) is a Foster City, California-based biopharmaceutical company best known for its HIV medicines, its Kite cell-therapy oncology business, and its liver-disease portfolio. Wall Street coverage skews bullish, with most tracked firms rating the stock Buy or Overweight.

Because the overall mean of all valid targets sits only about 6% above the latest price, the $190 figure used here is calculated as the average of the targets that exceed the current share price. Across 14 individually attributed targets reviewed, the range spans from $131 (RBC Capital) to $200 (Scotiabank and Needham), with an overall average of roughly $177. The 10 targets above the current price — from firms including J.P. Morgan ($190), UBS ($195), Citi ($188), Wells Fargo ($190), Morgan Stanley ($183), Truist ($181), TD Cowen ($175) and BMO Capital ($184) — average about $188.6, rounded to $190.

The gap between bullish and cautious views is wide. Optimists emphasize durable HIV cash flows and the Biktarvy patent extension, while firms such as Goldman Sachs ($155), Cantor Fitzgerald ($155) and Leerink Partners ($145) reflect a more restrained view of oncology progress and competitive pressures. These targets are individual forecasts, not guarantees.

Current Market Position and Path Toward the Target

GILD closed near $166.89 on November 6, 2026, not far below a 52-week high around $176.58. A move to $190 implies about 14% upside — a substantial move for a large-cap stock already up roughly 38% year-to-date. The path would likely depend on sustained HIV growth, continued oncology data readouts, and whether recent enthusiasm around ASH 2026 blood-cancer results and positive Livdelzi liver-disease data converts into durable multiple expansion.

What Could Support a Move Toward the Target

The core bull case centers on the HIV franchise. Biktarvy remains a key revenue driver, and the twice-yearly Yeztugo (lenacapavir) PrEP launch offers a new growth runway. Analysts at UBS and J.P. Morgan raised targets after Gilead's third-quarter beat, citing HIV momentum. Oncology optionality — including Kite's cell therapies and the anito-cel program — plus the Biktarvy patent extension and recent positive liver-disease data provide additional support. Third-quarter revenue grew about 6.8% year over year to $8.3 billion.

What Could Prevent the Target From Being Reached

Earnings quality is a concern: third-quarter EPS fell roughly 20% year over year to $1.94 on rising costs, and the second quarter included a large GAAP net loss tied to impairment charges. The FDA's approval of a first generic Yeztugo raises competitive risk to a key growth asset, and Gilead's oncology pipeline has produced mixed results. A valuation compression, a pullback in biotech sentiment, or policy and pricing uncertainty could all keep the stock below the $190 mark.

Technical Levels and Market Structure

GILD trades above its 50-day and 200-day moving averages, a constructive long-term setup, but it recently reversed sharply after touching a 52-week high in premarket trading — a sign of profit-taking near resistance. The area around $176–$178 now marks key resistance, while the $153–$155 zone offers nearby support. The psychological $200 level, which matches the highest analyst targets, would represent the next major milestone beyond $190.

Time Horizon and What Investors Should Monitor

Most analyst price targets reflect a research horizon of roughly 12 months, though individual firms may differ. Key items to watch include quarterly HIV and oncology sales, Yeztugo launch trends and generic competition, guidance updates, further pipeline and clinical data, and any regulatory or pricing-policy developments. Analyst revisions around earnings will be the most direct signal on whether the $190 target remains in view.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than through manual review alone. Consider exploring the platform to see how its AI-driven signals can complement your own research on GILD and the broader market.

Final Assessment

Can GILD reach $190? The question is not a forecast but a test of conviction in the HIV franchise and oncology pipeline. The $190 central target, derived from the average of above-price analyst targets, requires about a 14% advance from current levels. Durable HIV cash flows and new PrEP momentum support the case, while margin pressure, oncology uncertainty, and early Yeztugo generics are the principal obstacles. The wide $131-to-$200 analyst range shows genuine disagreement, making earnings, guidance, and data readouts the clearest indicators to monitor next.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

GILD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
-0.06%
AMGN - GILD
57%
Loosely correlated
-0.15%
ABBV - GILD
48%
Loosely correlated
+0.94%
MRK - GILD
47%
Loosely correlated
+0.69%
JNJ - GILD
46%
Loosely correlated
+1.25%
PFE - GILD
46%
Loosely correlated
-0.51%
More
Can Gilead Sciences (GILD) Stock Reach $190?